Document is current
Any future updates will be listed below
-
Authors
Kafol, Jan
Fras, Zlatko
Novakovic, Marko
Sperling, Laurence S.
Cevc, Matija
Krevel, Barbara
Kafol, Lenart
Kelenc, Anamarija
Kepic, Klarisa
Vrbinc, Katarina
Svarc, Miha
Groselj, Urh
Jug, Borut
-
Funding
Funding for this research was provided by:
The Slovenian Research and Innovation Agency (V3-24038)
The Slovenian Research and Innovation Agency (P3-0343)
The Slovenian Research and Innovation Agency (P3-0308)
- License Information
-
More Information
Article History
Received: 7 January 2026
Accepted: 12 February 2026
First Online: 5 March 2026
Declarations
:
: The study was approved by the Slovenian National Medical Ethics Committee (No. 22/01/2017; 0120 − 14/2017-2; 0120 − 14/2017-5). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to inclusion in the dyslipidemia registry.
: J.K. received speaking honoraria from Medison Pharma. Z.F. received speaker honoraria / consultancy fees from Novo Nordisk, Swixx Biopharma and Amgen. Z.F. received research funding from Novartis. Z.F. research work was supported by the Slovenian Research and Innovation Agency Program J3-4525. M.N. and B.K. received speaking honoraria from Novartis, Swixx Biopharma, Amgen and Krka. L.S.S. serves as the Chief Medical Officer of the Family Heart Foundation. U.G. received speaking honoraria from Novartis, AstraZeneca and Ultragenyx. U.G. research work was supported by the Slovenian Research and Innovation Agency Program P3-0343. B.J. research work was supported by the Slovenian Research and Innovation Agency Program V3-24038. Other authors declare no conflict of interest.
